Holds one active US DMF for dalfampridine, filing since 2018. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 20 markets.
Holds one active US DMF for dalfampridine, filing since 2013. Its GMP is recognised in 21 markets.
Holds one active US DMF for dalfampridine, filing since 2025. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Holds one active US DMF for dalfampridine, filing since 2014. Its 2025 FDA inspection closed as VAI.
Registered with SFDA (Saudi Arabia) for dalfampridine. Its 2022 FDA inspection closed as VAI.
Holds one active US DMF for dalfampridine, filing since 2004. Its 2021 FDA inspection closed as VAI.
Holds one active US DMF for dalfampridine, filing since 2011. Its GMP is recognised in 2 markets.
Holds one active US DMF for dalfampridine, filing since 2013. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for dalfampridine, filing since 2013. Its 2022 FDA inspection closed as VAI.
Registered with SFDA (Saudi Arabia) for dalfampridine. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Registered with SFDA (Saudi Arabia) for dalfampridine. Its GMP is recognised in 6 markets.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free